From YMB-- This is mostly going to be a replac
Post# of 30067
Posted On: 11/18/2014 10:51:38 AM
From YMB--
This is mostly going to be a replacement for Lympro if the Company decides to sell. If you look at the option structure, it is likely the Company is planning to sell Lympro in 2015 and simulanteously exercise to acquire the ESS assets. So I guess say if the Company is able to sell Lympro for ~$100MM...
$15MM would go into SG&A (estimately 2015/2016 cash burn)
$20MM kept on hand for additional R&D/Acquisitions
$10MM payoff all areas surrounding ESS
Roughly $55MM can be paid out as a shareholder dividend of $0.068/share (that's about a million each for daddy commish and gcommish).
The numbers are up to management discretion of course, but if you look the proposition, it really is "1+1=10"
This is mostly going to be a replacement for Lympro if the Company decides to sell. If you look at the option structure, it is likely the Company is planning to sell Lympro in 2015 and simulanteously exercise to acquire the ESS assets. So I guess say if the Company is able to sell Lympro for ~$100MM...
$15MM would go into SG&A (estimately 2015/2016 cash burn)
$20MM kept on hand for additional R&D/Acquisitions
$10MM payoff all areas surrounding ESS
Roughly $55MM can be paid out as a shareholder dividend of $0.068/share (that's about a million each for daddy commish and gcommish).
The numbers are up to management discretion of course, but if you look the proposition, it really is "1+1=10"
(0)
(0)